Innovations & Thérapeutiques en Oncologie
MENUMethodological challenges for precision medicine in oncology Volume 3, issue 1, January-February 2017
Figures
Université Paris Sud et Comité statistique de ARCAGY-GINECO
Rue Ampère
91405 Orsay Cedex
France
Service de biostatistique et d’epidémiologie & INSERM CESP
114, rue Edouard Vaillant
94805 Villejuif cedex
France
- Key words: precision medicine, targeted therapy, clinical trial, early trial, biomarker
- DOI : 10.1684/ito.2017.0071
- Page(s) : 33-8
- Published in: 2017
New methods have been required for evaluating targeted therapies, as the classic sequence – phase I: toxicity; phase II: efficacy; phase III: comparison with standard treatment – is no longer effective. As the parallelism between dose-toxicity and dose-efficacy, which was observed for cytotoxic chemotherapies, can no longer be supported, early trials are required to simultaneously assess toxicity and early signals of efficacy, based on biomarkers when available. Phase II primary endpoints have also been brought into question, as RECIST criteria are not well-suited to functional modifications in the tumour. New phase III trials, including more homogeneous targeted populations, will use more flexible designs, including interim analyses and adaptive design, allowing the sample size, and sometimes the trial design, to be modified during the course of the trial. This article discusses these new methodological challenges.